Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease

Kidney International

Volumn 83, Issue 5, 2013, Pages 915-923

  Idorn, Thomas ^a   Knop, Filip K ^a,b   Jørgensen, Morten ^a   Holst, Jens J ^b   Hornum, Mads ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

end stage renal disease (ESRD); gastrointestinal mediated glucose disposal (GIGD); glucagon; glucagon like peptide 1 (GLP 1); glucose dependent insulinotropic polypeptide (GIP); incretin effect

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY FAILURE; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 84877040819     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.460     Document Type: Article

References (39)

1. Alvestrand A, Mujagic M, Wajngot A et al. Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance. Clin Nephrol 1989; 31: 175-183.
2. Bilbrey GL, Faloona GR, White MG et al. Hyperglucagonemia of renal failure. J Clin Invest 1974; 53: 841-847.
3. DeFronzo RA. Pathogenesis of glucose intolerance in uremia. Metabolism 1978; 27: 1866-1880.
4. Hornum M, Clausen P, Kjaergaard J et al. Pre-diabetes and arterial stiffness in uraemic patients. Nephrol Dial Transplant 2010; 25: 1218-1225.
5. Eldin WS, Ragheb A, Klassen J et al. Evidence for increased risk of prediabetes in the uremic patient. Nephron Clin Pract 2008; 108: c47-c55.
6. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
7. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573.
8. Nauck M, Stockmann F, Ebert R et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
9. Bagger JI, Knop FK, Lund A et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 737-745.
10. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
11. Knop FK, Vilsboll T, Madsbad S et al. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797-805.
12. Knop FK, Vilsboll T, Hojberg PV et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
13. Hare KJ, Vilsboll T, Holst JJ et al. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 2010; 298: E832-E837.
14. Holst JJ, Knop FK, Vilsboll T et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34(Suppl 2): S251-S257.
15. Hansen KB, Vilsboll T, Bagger JI et al. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 2010; 95: 3309-3317.
16. Knop FK, Vilsboll T, Larsen S et al. Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regul Pept 2010; 164: 144-150.
17. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med 1971; 285: 443-449.
18. Shah P, Basu A, Basu R et al. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277: E283-E290.
19. Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28: 574-578.
20. Ascaso JF, Pardo S, Real JT et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
22. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
24. Pham H, Utzschneider KM, de Boer IH. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 640-646.
25. Lauritzen JB, Lauritsen KB, Olsen ME et al. Gastric inhibitory polypeptide (GIP) and insulin release in response to oral and intravenous glucose in uremic patients. Metabolism 1982; 31: 1096-1099.
26. Muscelli E, Mari A, Natali A et al. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 2006; 291: E1144-E1150.
27. O'Dorisio TM, Sirinek KR, Mazzaferri EL et al. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism 1977; 26: 651-656.
28. Owyang C, Miller LJ, DiMagno EP et al. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc 1979; 54: 769-773.
29. Meier JJ, Nauck MA, Kranz D et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-662.
30. Ruiz-Grande C, Alarcon C, Alcantara A et al. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 1993; 25: 612-616.
31. Henkel E, Menschikowski M, Koehler C et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005; 54: 1168-1173.
32. Muller WA, Faloona GR, guilar-Parada E et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
33. Reaven GM, Chen YD, Golay A et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110.
34. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992; 74: 379-384.
35. Sherwin RS, Bastl C, Finkelstein FO et al. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest 1976; 57: 722-731.
36. Lund A, Vilsboll T, Bagger JI et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011; 300: E1038-E1046.
37. Klose M, Brennum J, Poulsgaard L et al. Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2010; 73: 95-101.
38. Lindgren O, Carr RD, Deacon CF et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. Ser B 1995; 57: 289-300.